Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Preemption Policy Gets First Appeals Court Test With Zoloft, Paxil Cases

Executive Summary

A federal appellate court will take up the issue of whether FDA approved labeling preempts state litigation claiming companies failed to warn of a product's risks, following years of conflicting rulings from district courts

You may also be interested in...



FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008

As 2007 came to an end, lawyers, judges and others involved in pharmaceutical litigation had just one word on their minds: preemption

FDA Preemption Cases Expected To Stay On Top Of Legal Calendar In 2008

As 2007 came to an end, lawyers, judges and others involved in pharmaceutical litigation had just one word on their minds: preemption

Pharma Companies Swat Down Novel Theories Of Product Liability

For the last five years, brand name companies have been pulled into court to battle claims that they are liable for injuries caused by a generic version of their drug

Related Content

UsernamePublicRestriction

Register

PS048222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel